Menu

Generics/General

Australia flag V13C29

Why choose generic medicines initiative launched in Australia

Generics/General | Posted 29/03/2013

The Australian Generic Medicines Industry Association (GMiA) and the Pharmacy Guild of Australia announced on 22 March 2013 the launch of a joint initiative: Why choose generic medicines?

India V13C03

India may move away from compulsory licensing

Generics/General | Posted 15/03/2013

The Indian Government, in a move that goes away from recent decisions, has suggested that the prices of patented pharmaceutical drugs be controlled by linking them to the country’s per capita income rather than by issuing compulsory licences.

picture26

UN urges WTO to keep cheap drug deal for poor countries

Generics/General | Posted 08/03/2013

Two United Nations (UNs) agencies are urging the extension of an exemption for least-developed countries on patent protection to ensure that HIV/AIDS and other lifesaving drugs remain affordable for the poor.

picture 125

French Government pushing generics

Generics/General | Posted 11/01/2013

The French are in general mistrusting of generics with many choosing to stay with brand-name drugs. However, with rising healthcare costs and austerity measures hitting healthcare budgets, the French Government has had to introduce measures to increase generic drug use in the country.

picture 96

India urged to drop cost-based drug policy

Generics/General | Posted 30/11/2012

Indian industry trade group the Associated Chambers of Commerce and Industry of India (ASSOCHAM) has urged the Indian Government to drop its cost-based price controls on both brand-name and generic drugs and instead introduce a market-based pricing policy.

picture 79

Momenta versus Amphastar and the safe harbour provision

Generics/General | Posted 26/10/2012

On 3 August 2012, the US Federal Circuit issued a decision holding that the safe harbour* provision of the Hatch-Waxman Act 35 U.S.C. § 271(e)(1) covers post-approval testing as long as it is ‘reasonably related’ to the submission of information to FDA. The case involved was that of Momenta Pharmaceuticals (Momenta) versus Amphastar Pharmaceuticals (Amphastar) (Federal Circuit No. 2012-1062, 8/3/12).

picture60

FDA gives generics greater importance

Generics/General | Posted 12/10/2012

The Office of Generic Drugs has been promoted to the highest position within FDA because of the great amount of work and income/expenditure now associated with generics.

picture36

Canada takes another step towards generics

Generics/General | Posted 21/09/2012

For the first time, two of Canada’s biggest health insurance companies are going to require that generics be prescribed if one is available.

picture24

Poor quality pharma ingredients abound in China

Generics/General | Posted 14/09/2012

Lack of regulatory enforcement in China is allowing poor quality pharmaceutical ingredients to be sold to drug manufacturers with potentially dangerous or even fatal consequences for patients.

picture21

Austria could save Euros 256 million by using more generics

Generics/General | Posted 07/09/2012

A recent study by IMS Health Austria (IMS) revealed that in Austria healthcare payers could have saved more than a quarter billion Euros during 2011 if physicians would have prescribed more generics to their patients.